Iodine-125 brachytherapy for brain tumours - a review

85Citations
Citations of this article
98Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Iodine-125 brachytherapy has been applied to brain tumours since 1979. Even though the physical and biological characteristics make these implants particularly attractive for minimal invasive treatment, the place for stereotactic brachytherapy is still poorly defined.An extensive review of the literature has been performed, especially concerning indications, results and complications. Iodine-125 seeds have been implanted in astrocytomas I-III, glioblastomas, metastases and several other tumour entities. Outcome data given in the literature are summarized. Complications are rare in carefully selected patients.All in all, for highly selected patients with newly diagnosed or recurrent primary or metastatic tumours, this method provides encouraging survival rates with relatively low complication rates and a good quality of life. © 2012 Schwarz et al; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Schwarz, S. B., Thon, N., Nikolajek, K., Niyazi, M., Tonn, J. C., Belka, C., & Kreth, F. W. (2012, March 6). Iodine-125 brachytherapy for brain tumours - a review. Radiation Oncology. https://doi.org/10.1186/1748-717X-7-30

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free